Swedish biopharma company Calliditas Therapeutics AB (STO:CALTX) on Friday reported positive topline data from its Phase 2b TRANSFORM trial evaluating setanaxib, a NOX enzyme inhibitor, in patients with primary biliary cholangitis (PBC) and elevated liver stiffness.
The trial met its primary endpoint, demonstrating statistically significant improvement in ALP (Alkaline Phosphatase) for both setanaxib doses versus placebo and positive trends on liver stiffness assessed by FibroScan at 24 weeks. Over 40% of patients were on dual or triple therapy, indicating setanaxib's potential incremental benefit beyond standard care.
Setanaxib treatment was generally well tolerated.
Calliditas is continuing clinical development with setanaxib, anticipating topline data in IPF (idiopathic pulmonary fibrosis) in Q4 2024/Q1 2025 and in Alport syndrome in 2025.
Indivior updates on Aelis Farma's Phase 2B study of AEF0117 for Cannabis Use Disorder
Vesper Bio announces positive Phase I results for FTD treatment
Empower Pharmacy names new president
Innovent's IBI363 receives US FDA Fast Track Designation
Valneva and Pfizer report positive Phase 2 booster results for Lyme disease vaccine
Grit Biotechnology's GT201 receives US FDA IND approval
Cereno Scientific doses first patient in Expanded Access Program for PAH
Medicilon USA begins operations at second R&D centre in Massachusetts
CS Genetics names new chief operating officer and chief scientific officer
Expanse Medical names new chief executive officer and FlowPhysix board member